Relmada Therapeutics Acquires Sepranolone from Asarina Pharma for ~$3.12M

Shots:

• Relmada acquired the Sepranolone from Asarina for $3.12M via an asset purchase agreement to develop it as a potential treatment for Tourette syndrome (TS) & other compulsive disorders
• Sepranolone (10mg, BIW, SC) is a GABAA-modulating steroid antagonist that is being investigated in a P-IIa trial, assessing it with SoC vs SoC alone in TS pts (n=26) for 12wks.
• Trial met its 1EP of 28% tic severity reduction (measured by YGTSS), alongside its 2EPs of 69% greater quality of life improvement (GTS-QOL), 50% greater impairment reduction (YGTSS), & 44% greater reduction in the premonitory urge to tic (PUTS) with no CNS off-target effects

Ref: Relmada Therapeutics | Image: Relmada Therapeutics

Related News:- Relmada Therapeutics Reported Results for REL-1017 in the P-III Trial for the Treatment of Major Depressive Disorders

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com